(Q34424659)

2 August 2017

1 reference

title

Interferon in relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

2 August 2017

0 references

0 references

author name string

G P Rice

1

1 reference

2 August 2017

B Incorvaia

2

1 reference

2 August 2017

L Munari

3

1 reference

2 August 2017

G Ebers

4

1 reference

2 August 2017

C Polman

5

1 reference

2 August 2017

R D'Amico

6

1 reference

2 August 2017

G Filippini

7

1 reference

2 August 2017

publication date

1 January 2001

1 reference

Cochrane Database of Systematic Reviews

2 August 2017

published in

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

CD002002

1 reference

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Anticytokine antibodies in beta-interferon-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Systemic alpha-interferon therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Progress in determining the causes and treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002002

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

21 January 2018

1 reference

12 December 2020

Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis

1 reference

12 December 2020

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

1 reference

12 December 2020

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

12 December 2020

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Use of the FIM instrument in a trial of intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.

1 reference

12 December 2020

Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis

1 reference

12 December 2020

On the evaluation of disability in multiple sclerosis

1 reference

12 December 2020

Interferon beta in multiple sclerosis

1 reference

12 December 2020

The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis

1 reference

12 December 2020

Does interferon beta cause initial exacerbation of multiple sclerosis?

1 reference

12 December 2020

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist

1 reference

12 December 2020

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment

1 reference

12 December 2020

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

12 December 2020

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

1 reference

12 December 2020

Clinical trial of natural alpha interferon in multiple sclerosis

1 reference

12 December 2020

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

10.1002/14651858.CD002002

Identifiers

DOI

1 reference

release_3cg5r4pkrndcdmqm7zqvqnnhrm

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3cg5r4pkrndcdmqm7zqvqnnhrm

24 November 2022

mapped directly with Wikidata item

1 reference